Spectrila

Spectrila


Project Description

Active Ingredient: Recombinant Asparaginase 10,000IU

Dosage Form: Powder for concentrate for solution for infusion

Indication: A component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.

Packaging: Box of 1 or 5 vials

Manufacturer:

  • Rentschler Biotechnologie GmbH – Germany
  • Batch release: Medac Gesellschaft für klinische Spezialpräparate mbH – Germany